Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

by Dent, R.A, Lindeman, G.J, Clemons, M, Wildiers, H, Chan, A, McCarthy, N.J, Singer, C.F, Lowe, E.S, Watkins, C.L, Carmichael, J
Published 2020

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

by Trudeau, M.E, Chapman, J.-A.W, Guo, B, Clemons, M.J, Dent, R.A, Jong, R.A, Kahn, H.J, Pritchard, K.I, Han, L, O’Brien, P, Shepherd, L.E, Parissenti, A.M
Published 2020